EVARREST
Biological
Medical Device Business Services, Inc.
Total Payments
$1.0M
Transactions
2,493
Doctors
1,590
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $257,495 | 690 | 379 |
| 2023 | $188,930 | 451 | 314 |
| 2022 | $69,860 | 416 | 368 |
| 2021 | $55,711 | 40 | 16 |
| 2020 | $83,854 | 31 | 7 |
| 2019 | $137,672 | 33 | 7 |
| 2018 | $63,577 | 52 | 19 |
| 2017 | $161,475 | 780 | 593 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $591,904 | 224 | 58.1% |
| Unspecified | $271,080 | 89 | 26.6% |
| Food and Beverage | $83,762 | 1,975 | 8.2% |
| Travel and Lodging | $52,422 | 190 | 5.1% |
| Space rental or facility fees (teaching hospital only) | $17,407 | 13 | 1.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000 | 2 | 0.2% |
Payments by Type
General
$747,494
2,404 transactions
Research
$271,080
89 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitonea l, Pelvic and Thoracic (non-cardiac) Surgery in Pediatric Patients | Ethicon Inc. | $95,103 | 0 |
| A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitonea l, Pelvic and Thoracic (non-cardiac) Surgery in Pediatric Patients | Medical Device Business Services, Inc. | $69,619 | 0 |
| A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitonea l, Pelvic and Thoracic (non-cardiac) Surgery in PediatricPatients | Medical Device Business Services, Inc. | $31,030 | 0 |
| A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal Retroperitonea l Pelvic and Thoracic noncardiac Surgery in Pediatr | Ethicon Inc. | $29,776 | 0 |
| A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal Retroperitonea l Pelvic and Thoracic noncardiac Surgery in Pediatric Patients | Ethicon Inc. | $21,969 | 0 |
| Hemorrhage Control in Trauma Patients | Ethicon Inc. | $17,700 | 0 |
| EVARREST CV Phase III | Medical Device Business Services, Inc. | $5,883 | 0 |
Top Doctors Receiving Payments for EVARREST — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA-C | Physician Assistant | Boston, MA | $1,035 | 11 |
| , MD | Surgery | Pittsburgh, PA | $760.93 | 4 |
| , MD | Pediatric Surgery | Birmingham, AL | $741.07 | 6 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Pittsburgh, PA | $676.22 | 5 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Great Neck, NY | $674.68 | 4 |
| , MD | Surgery | Pennington, NJ | $605.42 | 4 |
| , PA | Physician Assistant | Oroville, CA | $515.64 | 7 |
| , MD | Neurological Surgery | Philadelphia, PA | $515.00 | 1 |
| , NURSE PRACTITIONER | Family | Hacienda Heights, CA | $510.46 | 6 |
| Nidal Alkafarna | Surgical | Los Angeles, CA | $510.46 | 6 |
| , M.D | Orthopaedic Surgery | Philadelphia, PA | $450.00 | 1 |
| , M.D | Orthopaedic Surgery | Colorado Springs, CO | $450.00 | 1 |
| , PA-C | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Torrance, CA | $440.83 | 5 |
| , PA-C | Surgical | Rancho Santa Margarita, CA | $440.33 | 5 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Indianapolis, IN | $417.98 | 2 |
| Jenniflor Paulo | Acute Care | Upland, CA | $378.84 | 6 |
| Alexandra Kharazi | Surgery | Chula Vista, CA | $305.72 | 4 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Austin, TX | $267.69 | 3 |
| Jay Coates | Surgery | Las Vegas, NV | $251.53 | 5 |
| , MD | Vascular Surgery | Dartmouth, MA | $243.68 | 2 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Indianapolis, IN | $238.02 | 3 |
| , PA-C | Surgical | Springfield, OR | $234.35 | 5 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Jackson, MS | $225.30 | 2 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Jackson, MS | $225.30 | 2 |
| , PA-C | Physician Assistant | Rock Hill, SC | $224.09 | 4 |
Ad
Manufacturing Companies
- Medical Device Business Services, Inc. $574,589
- Ethicon Inc. $272,622
- Ethicon US, LLC $170,867
- DePuy Synthes Products LLC $450.00
- Janssen Pharmaceuticals, Inc $45.52
Product Information
- Type Biological
- Total Payments $1.0M
- Total Doctors 1,590
- Transactions 2,493
About EVARREST
EVARREST is a biological associated with $1.0M in payments to 1,590 healthcare providers, recorded across 2,493 transactions in the CMS Open Payments database. The primary manufacturer is Medical Device Business Services, Inc..
Payment data is available from 2017 to 2024. In 2024, $257,495 was paid across 690 transactions to 379 doctors.
The most common payment nature for EVARREST is "Consulting Fee" ($591,904, 58.1% of total).
EVARREST is associated with 7 research studies, including "A Prospective Study Evaluating the Safety and Effectiveness of EVARREST Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitonea l, Pelvic and Thoracic (non-cardiac) Surgery in Pediatric Patients" ($95,103).